Conversely, sedentary patients or those engaging only in cardiovascular exercise without resistance components will experience greater muscle loss
Glapp is a support tool, not a healthcare provider
Social media is full of discussions about weight-loss injections, dramatic transformations
Second, the off-label adoption pattern that the longevity reframing will inevitably accelerate is going to produce the next wave of monitoring, dosing, and selection problems, patients without obesity or diabetes do not have the diagnostic anchors (BMI, A1c, insulin resistance markers) that frame the on-label conversation, and the clinical infrastructure for managing GLP-1 therapy in metabolically healthy users is, charitably described, thin
At Klinic, we emphasize using FDA-approved brands like Wegovy because they guarantee consistent dosing and the robust safety profiles trusted by experts